title: Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters.
abstract: BACKGROUND
  Prostate cancer is the most common malignancy affecting men and is a major cause of cancer death. There are increasing data on novel tumor markers, such as gelatinase A, which play a key role in tissue invasion and metastasis.
  
  
  OBJECTIVE
  We designed a study to evaluate total gelatinase A content using a simple and applicable Indirect hemagglutination (IHA) test in harmony with gelatinase A activity in serum samples as compared with prostate-specifc antigen (PSA) parameters.
  
  
  METHODS
  In this study, we analysed the circulating form of gelatinase A (MMP-2) in patients suffering from either benign prostate hyperplasia (n=54) or prostate cancer (n=26) versus normal individuals as control (n=26). The gelatinolytic activity was determined by zymography and total MMP-2 content was measured by a novel IHA method. Total PSA and free PSA were quantified using a standard ELISA technique.
  
  
  RESULTS
  Correlation of densitometric analysis of gelatinase A activity and IHA titer is significant at the 0.01 level (P<0.01, rho=0.916). Correlation of PSA and IHA titer is significant at the 0.01 level (P<0.01, rho=0.746). Correlation of free PSA and IHA titer is significant at the 0.01 level (P<0.01, rho=0.749). Borderline of IHA titer in patients with prostate cancer was 512+/-1 tube titer, in benign prostate hyperplasia patients was 128+/-1 tube titer and the titer in normal individuals was 8+/-1 tube titer.
  
  
  CONCLUSIONS
  These results demonstrate that assessment of gelatinase A might be a promising procedure for monitoring and screening patients with prostate cancer.
authors.affiliation: School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran. khoramza@sina.tums.ac.ir
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Khorramizadeh
authors.forename: Nastaran
authors.initials: N
authors.lastname: Aalizadeh
authors.forename: Mohammad
authors.initials: M
authors.lastname: Pezeshki
authors.forename: Aziz
authors.initials: A
authors.lastname: Ghahary
authors.forename: Hojat
authors.initials: H
authors.lastname: Zeraati
authors.forename: Azar
authors.initials: A
authors.lastname: Berahmeh
authors.forename: Omid
authors.initials: O
authors.lastname: Safa
authors.forename: Farshid
authors.initials: F
authors.lastname: Saadat
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000201:enzymology*; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D006386:Hemagglutination Tests; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011469:Prostatic Diseases / Q000097:blood / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000097:blood* / Q000201:enzymology*
chemical_list: D017430:Prostate-Specific Antigen; D020778:Matrix Metalloproteinase 2